Alnylam Pharmaceuticals Inc.

15 trials 7 recruiting Commercial sponsor

Filter these 15 trials by condition, phase, country and more.

Open in Search →
15 Registered trials
7 Recruiting
9 Completed trials
22 Countries active
8 Unique IMPs
100% Results reported
Phase III: 8 Phase II: 1 Phase I/II: 1 Phase I: 4 Phase I (FiH): 1
100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cardiac amyloidosis 4 Hypertension 1 Hereditary haemorrhagic telangiectasia 1 Hyperoxaluria 1 Hepatocellular carcinoma 1 Type 2 diabetes mellitus 1 Cerebral amyloid angiopathy 1 Huntington's disease 1 Polyneuropathy 1 Cardiomyopathy 1 Hereditary neuropathic amyloidosis 1

Top IMPs

VUTRISIRAN 4 NUCRESIRAN 2 PATISIRAN 2 ALN-4324 1 ALN-961583 1 LUMASIRAN 1 RNA, (UM-SP-(2′-DEOXY-2′-FLUORO)A-SP-GM-AM-AM-(2′-DEOXY-2′-FLUORO)A-CM-UM-CM-AM-UM-AM-GM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)A-UM-UM-GM-CM-AM-SP-CM-SP-AM), COMPLEX WITH RNA (UM-SP-GM-SP-CM-AM-AM-UM-(2′-DEOXY-2′-FLUORO)C-GM-(2′-DEOXY-2′-FLUORO)C-(2′-DEOXY-2′-FLUORO)U-(2′-DEOXY-2′-FLUORO)A-UM-GM-AM-GM-UM-UM-UM-CM-UM-AM) 3′-[[(2S,4R)-1-[29-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-14,14-BIS[[3-[[3-[[5-[[2-(ACETYLAMINO)-2-DEOXY-Β-D-GALACTOPYRANOSYL]OXY]-1-OXOPENTYL]AMINO]PROPYL]AMINO]-3-OXOPROPOXY]METHYL]-1,12,19,25-TETRAOXO-16-OXA-13,20,24-TRIAZANONACOS-1-YL]-4-HYDROXY-2-PYRROLIDINYL]METHYL HYDROGEN PHOSPHATE] (1:1) 1 ZILEBESIRAN 1

All trials

15 total

Showing 1–15 of 15 trials

← All sponsors A–Z